

8EHQ-0245-13332

PUBLIC NOTICE COPY

8EHQ-95-13332

66950000/21

February 6, 1995

(A)

CERTIFIED MAIL  
RETURN RECEIPT REQUESTED  
P 253 155 587

95 FEB 13 AM 8:01

RECEIVED

OPPT Document Processing Center (7407)  
ATTN: Section 8(e) Coordinator  
Office of Pollution Prevention and Toxics (OPPT)  
US Environmental Protection Agency  
Washington, DC 20460

RE: TSCA Section 8(e) Notice

**COMPANY SANITIZED**

Dear Sir or Madam:

This notice is being submitted by Rhône-Poulenc Ag Company (RPAC) to the Environmental Protection Agency (EPA) in accordance with the provisions of Section 8(e) of the Toxic Substances Control Act (TSCA), 15 USC § 2607 (e).

We are submitting the results from a toxicity study in rats on . Only limited quantities of this compound have been synthesized for research and development purposes.

RPAC claims the alpha-numeric designation and the specific chemical identity of the substance at issue to be confidential business information (CBI). The chemical substance may be nonconfidentially identified as a "heterocycle".

Test material was administered by gavage at doses of 1, 5, and 15 mg/kg/day (7 male rats/group) for 14 days. Decreases in thyroxine and increases in liver weight were observed at 5 and 15 mg/kg/day. Thyroid stimulating hormone was increased at 15 mg/kg/day. Hepatic hypertrophy and mitosis were reported at 5 and 15 mg/kg/day and thyroid follicular hyperplasia was noted at all doses.

SUPPORT INFORMATION OF CONFIDENTIALITY CLAIMS

1. Claims of confidentiality are being made on behalf of RPAC.
2. RPAC asserts this claim of confidentiality until such time as a specific chemical is approved for use in the United States. In the event that the chemical is never approved, RPAC asserts that the CBI information should be provided permanent protection. The structure and use of the chemical are unique. Disclosure of this information would provide our competitors with information on facets of our business that would be detrimental to our competitive position.

2/08/95


## PUBLIC NOTICE COPY

3. The information claimed as confidential has not been previously disclosed to any other governmental agency or to EPA.
4. This information has been disclosed to only a very limited number of investigators outside of RPAC who have performed either toxicity or efficacy testing. These individuals operate under a strict secrecy agreement. Any individuals who may work with the chemical will have all health/toxicology information disclosed to them as well, but only on the basis of strict secrecy and respect for the CBI nature of the information.
5. Any individuals to whom the CBI is revealed are warned of the nature of the information. Further, they are informed of their obligations to maintain secrecy should they terminate their employment with RPAC.
6. None of the information claimed as confidential appears in or is referred to in any advertising or promotional materials for the chemical or the end product containing it, professional or trade publications, or any other media available to the public or to our competitors. Appropriate warnings do appear on safety data sheets, as RPAC considers that individuals who are requested to work with the chemicals have every right to know as much about the chemicals' toxicity as possible. Further, the information is only considered to be CBI with respect to the general public, insofar as our competitors could use the information in an unfairly competitive nature.
7. No previous confidentiality determinations have been made by EPA, other Federal agencies or courts in connection with this information.
8. RPAC believes that disclosure of this information to the general public would be likely to result in substantial harm to its competitive position. Disclosure of the **alpha numeric designation** and **chemical name** would provide some competitors with information about the specific chemistry of this area of our research and our business. Further, the type of toxicological testing being reported in the TSCA 8(e) notice would provide competitive information about this chemical's status in the research and development process and, therefore, the time remaining until commercialization.
9. A patent has not been issued for the specific chemical structure. However, the generic chemical structure is covered by a patent that is currently pending.
10. The chemical is not available commercially. It is in the earliest stages of research and development for pesticide use and is unlikely to be developed into a commercial product.
11. We believe that disclosure of the chemical name would allow a competitor to synthesize this chemical. RPAC has invested a large amount of time and money into research of this particular chemical family, and information on specific chemical structures would harm our competitive position.
12. Disclosure of the chemical structure might reveal information on processes used to synthesize this compound.
13. CAS number has not yet been assigned.
14. Currently, the chemical is not the subject of FIFRA regulation or reporting.

PUBLIC NOTICE COPY

Further questions regarding this submission may be directed to the undersigned at 919-549-2222.

Sincerely,

A handwritten signature in cursive script, appearing to read "Glenn S. Simon".

Glenn S. Simon, PhD, DABT  
Director of Toxicology



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY  
WASHINGTON, D.C. 20460

Glenn S. Simon, Ph.D., DABT  
Director of Toxicology  
Rhône-Poulenc  
P.O. Box 214  
2 T.W. Alexander Drive  
Research Triangle Park, North Carolina 27709

OFFICE OF  
PREVENTION, PESTICIDES AND  
TOXIC SUBSTANCES

APR 18 1995

EPA acknowledges the receipt of information submitted by your organization under Section 8(e) of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and refer to the reverse side of this page for "EPA Information Requests".

All TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 11110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

Document Processing Center (7407)  
Attn: TSCA Section 8(e) Coordinator  
Office of Pollution Prevention and Toxics  
U.S. Environmental Protection Agency  
Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,

*Terry R. O'Bryan*

Terry R. O'Bryan  
Risk Analysis Branch

Enclosure

13332A



Recycled/Recyclable  
Printed with Soy/Canola Ink on paper that  
contains at least 50% recycled fiber

### Triage of 8(e) Submissions

Date sent to triage: APR 19 1995

NON-CAP

CAP

Submission number: 13332A

TSCA Inventory:

Y

N

G

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

ECO

AQUATO

Group 2 - Ernie Falke (1 copy total)

ATOX

SBTOX

SEN

w/NEUR

Group 3 - Elizabeth Margosches (1 copy each)

STOX

CTOX

EPI

RTOX

GTOX

STOX/ONCO

CTOX/ONCO

IMMUNO

CYTO

NEUR

Other (FATE, EXPO, MET, etc.):

Notes:

**THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY**

#### For Contractor Use Only

entire document: 0

1

2

pages

4, 2, 3

pages

4, 2, 3

Notes:

Contractor reviewer:

PR

Date:

4/3/95

CECATS/TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA: Submission # 8EHQ-0295-13332 5 SEQ. A  
 TYPE: INT. SUPP FLWP  
 SUBMITTER NAME: Rhone-Poulenc Ag Company

INFORMATION REQUESTED: FLWP DATE:  
 0501 NO INFO REQUESTED  
 0502 INFO REQUESTED (TECH)  
 0503 INFO REQUESTED (VOL ACTIONS)  
 0504 INFO REQUESTED (REPORTING RATIONALE)  
 DISPOSITION:  
 0639 REFER TO CHEMICAL SCREENING  
 0678 CAP NOTICE

OPTIONARY ACTIONS:  
 0401 NO ACTION REPORTED  
 0402 STUDIES PLANNED (INDIVIDUAL)  
 0403 NOTIFICATION OF WORKING  
 0404 LABEL/MSDS (TIANGLIS)  
 0405 PROCESS/HANDLING (TIANGLIS)  
 0406 APP/USE DISCONTINUED  
 0407 PRODUCTION DISCONTINUED  
 0408 CONFIDENTIAL

SUB. DATE: 02/06/95 OTS DATE: 02/13/95 CSRAD DATE: 02/28/95

CHEMICAL NAME: Heterocycle CAS# Confident

INFORMATION TYPE:	P F C	INFORMATION TYPE:	P F C	INFORMATION TYPE:	P F C
0201 ONCO (HUMAN)	01 02 04	0216 EPI/CLIN	01 02 04	0241 IMMUNO (ANIMAL)	01 02 04
0202 ONCO (ANIMAL)	01 02 04	0217 HUMAN EXPOS (PROD CONTAM)	01 02 04	0242 IMMUNO (HUMAN)	01 02 04
0203 CELL TRANS (IN VITRO)	01 02 04	0218 HUMAN EXPOS (ACCIDENTAL)	01 02 04	0243 CHEMPHYS PROP	01 02 04
0204 MUTA (IN VITRO)	01 02 04	0219 HUMAN EXPOS (MONITORING)	01 02 04	0244 CLASTO (IN VITRO)	01 02 04
0205 MUTA (IN VIVO)	01 02 04	0220 ECO/AQUA TOX	01 02 04	0245 CLASTO (ANIMAL)	01 02 04
0206 REPRO/TERATO (HUMAN)	01 02 04	0221 ENV. OCCURENCE/FATE	01 02 04	0246 CLASTO (HUMAN)	01 02 04
0207 REPRO/TERATO (ANIMAL)	01 02 04	0222 EMER INCI OF ENV CONTAM	01 02 04	0247 DNA DAM/REPAIR	01 02 04
0208 NEURO (HUMAN)	01 02 04	0223 RESPONSE REQUEST DELAY	01 02 04	0248 PROD/USE/PROC	01 02 04
0209 NEURO (ANIMAL)	01 02 04	0224 PROD/COMP/CHEM ID	01 02 04	0251 MSDS	01 02 04
0210 ACUTE TOX. (HUMAN)	01 02 04	0225 REPORTING RATIONALE	01 02 04	0299 OTHER	01 02 04
0211 CHR. TOX. (HUMAN)	01 02 04	0226 CONFIDENTIAL	01 02 04		
0212 ACUTE TOX. (ANIMAL)	01 02 04	0227 ALLERG (HUMAN)	01 02 04		
0213 SUB ACUTE TOX (ANIMAL)	01 02 04	0228 ALLERG (ANIMAL)	01 02 04		
0214 SUB CHRONIC TOX (ANIMAL)	01 02 04	0229 METAB/PHARMACO (ANIMAL)	01 02 04		
0215 CHRONIC TOX (ANIMAL)	01 02 04	0240 METAB/PHARMACO (HUMAN)	01 02 04		

TRIAGE DATA: NON-CBI INVENTORY YES YES (DROP/REFER) NO (CONTINUE) REFTR

SPECIES RAT TOXICOLOGICAL CONCERN: LOW MED HIGH

USE: R.D. Pesticide PRODUCTION:

CAS SR NO IN IT Non-Cap

8 (E) -13332A

H

SUBACUTE ORAL TOXICITY IN MALE RATS IS OF HIGH CONCERN. DOSAGES (GAVAGE, 14 DAYS, 7/GROUP) WERE 1 MG/KG/DAY; 5 MG/KG/DAY; AND 15 MG/KG/DAY. MORTALITY INCIDENCES WERE NOT REPORTED. AT 5 AND 15 MG/KG/DAY, PATHOLOGICAL SIGNS INCLUDED DECREASED THYROXINE AND INCREASED LIVER WEIGHT; AND HEPATIC HYPERTROPHY AND MITOSIS WERE OBSERVED. AT 15 MG/KG/DAY, THERE WAS INCREASED THYROID STIMULATING HORMONES. AT ALL DOSE LEVELS, THYROID FOLLICULAR HYPERPLASIA WAS NOTED.